25th August 2016

Luxury Goods

h

	1 M	3 M	6 M	31/12/15
Pers & H/H Gds	1.4%	2.0%	8.9%	3.4%
DJ Stoxx 600	1.4%	0.2%	7.7%	-5.7%
*Stoxx Sector Indices				

Companies covered				
BURBERRY		NEUTRAL	1200p	
Last Price	1353p	Market Cap.	GBP6,004m	
CHRISTIAN DIOR		BUY	EUR175	
Last Price	EUR161,2	Market Cap.	EUR29,294m	
HERMES Intl		BUY	EUR370	
Last Price	EUR389,95	Market Cap.	EUR41,167m	
HUGO BOSS		NEUTRAL	EUR74	
Last Price	EUR57,53	Market Cap.	EUR4,050m	
KERING		BUY	EUR175	
Last Price	EUR172,15	Market Cap.	EUR21,737m	
LVMH		BUY	EUR171	
Last Price	EUR157,3	Market Cap.	EUR79,867m	
MONCLER		BUY	EUR17,5	
Last Price	EUR15,59	Market Cap.	EUR3,900m	
PRADA		NEUTRAL	HKD35	
Last Price	EUR21,2	Market Cap.	EUR54,247m	
RICHEMONT		NEUTRAL	CHF63	
Last Price	CHF59,2	Market Cap.	CHF33,152m	
SALVATORE F	ERRAGAMO	BUY	EUR23	
Last Price	EUR20,95	Market Cap.	EUR3,536m	
THE SWATCH GROUP		SELL	CHF270	
Last Price	CHF262,7	Market Cap.	CHF14,552m	
TOD'S GROUP	b	SELL	EUR53	
Last Price	EUR54,3	Market Cap.	EUR1,797m	



A soft H1 but not so disastrous!

In H1 2016, Luxury groups were clearly affected by a quite challenging environment (lower tourist flows in Europe and uncertain situation in the US) with an average 1% organic sales growth after +3% in FY 2015. Profitability was generally slightly under pressure following almost no sales growth (despite costs control), highlighting some deleverage impact. We still favour Moncler (Buy-FV: EUR17.5), LVMH (Buy-FV: EUR171) and Kering (Buy-FV: EUR175). Meanwhile, we remain very cautious short term on Tod's Group (Sell-FV: EUR53) and on The Swatch Group (Sell-FV: CHF270).

ANALYSIS

- As expected, H1 Luxury Goods results were mixed with some reassuring publications like Moncler (Buy-FV: EUR17.5), Hermès (Buy-FV: EUR370), LVMH (Buy-FV: EUR171) and Kering (Buy-FV: EUR175), but some others were quite disappointing such as The Swatch Group (Sell-FV: CHF270) and Tod's (Sell-FV: EUR53). Globally, H1 sales grew 1% organically following +3% in FY 2015. In Q2 alone, sales were slightly above 1% while in Q1, they was slightly below 1%, with the deviation coming from Hermes. Nevertheless, if we exclude Moncler, revenues were down 1% in both quarters highlighting a challenging environment.
- By geographical area, we would highlight the clear slowdown in Europe with for instance 3% revenue growth in Q2 at LVMH vs +7% in Q1 and for Kering from +10% in Q1 to +5% in Q2. Nevertheless, Hermès reported a very high sales increase in Q2 too. Unsurprisingly, tourist flows have significantly decreased following the terror attacks across Europe and the state of emergency in France. For instance, Japanese tourists were 47% lower than in H1 2015 to visit Paris and Americans were also 6% lower than in H1 2015, Chinese 20% lower and Russian 35% lower.
- On the other hand, momentum clearly improved in Asia-Pacific, particularly in Q2 thanks to a slight increase in Mainland China while trends remained negative in H-K/Macau (in the double-digits). In Mainland China, activity was better since the Chinese clientele bought more at home, as a consequence of tightened custom controls, unfavourable currency moves (higher JPY) and safety concerns in Europe. Actually LVMH APAC sales declined 3% in Q1 but grew 3% in Q2 and Kering revenues there were respectively stable and up 6%.

Quarterly organic sales growth

in %	Q1 16	Q2 16	H1 16
Burberry	-2	-3	-4
Ferragamo	-2	-3	-3
Hermès	6	8	7
Hugo Boss	-3	-1	-2
Kering	4	7	6
o/w Kering Luxury	3	5	4
LVMH	3	4	4
o/w F&L division	0	1	4
Moncler	17	17	17
The Swatch Group	-12	-12	-12
Tod's group	-4	-4	-4
Average	1	1	1

Source: Company Data; Bryan Garnier & Co. ests.

Unsurprisingly, Hermès was amongst the best-performers in H1 with 7.2% organic sales growth (of which +8.1% in Q2 after +6% in Q1), driven by Leather goods (+16.3% and +17.1% in Q2), partly thanks to additional production capacities. Sales were up 8% in Europe during the half year, of which +7.3% in France with even an acceleration in Q2. Hermès' performance has to be compared with average Luxury goods industry revenues up 1%. Again Hermès clearly outperformed peers. And RMS H1 EBIT margin should be up around 100bp. Kering reported higher sales growth than expected by investors (+5.5% vs +4% expected), particularly for the luxury division. In Q2, Gucci brand performance was much stronger (+7.4%) than anticipated (+2%) and highlights the fact that brand renovation is underway with 70% of sales achieved with the Alessandro Michele collection. Nevertheless, Bottega Veneta revenues were down 9%, as the brand is over-exposed to Asian clients (70% of sales). Kering's profitability improved 20bp to 14.2% in H1 thanks to an 80bp gain to 27.6% for Gucci given a slight operating leverage and a less negative FX impact.


(To be continued next page)

- The other good surprise in the H1 release was LVMH which reported a 4% organic sales increase of which +1% for the Leather Goods & Fashion division vs 0% in Q1. We assume that Louis Vuitton sales were up around 2% in Q2. On the other hand, Wines & Spirits and Perfumes & Cosmetics activities were very well oriented with respectively 13% and 6% increases in Q2. These figures highlight the clear strength of the French group given the current challenging environment: it is the most diversified group among our luxury sample. Nevertheless, H1 EBIT margin was down 50bp to 17.2%, including -30bp for the Fashion & Leather business despite almost stable profitability for Louis Vuitton.
- The first half was quite heterogeneous for two groups exposed to the apparel category: **Moncler** achieved the highest growth in the sector (+17% FX-n o/w SSSG of +5%) as it outperforms a healthy outerwear segment (+5%/year) thanks to its heritage, strong legitimacy and luxury positioning. As such, Moncler has posted strong performances in two challenging regions: +30% in Asia-Pacific and +20% in the Americas. On the other hand, **Hugo Boss** (-2% FX-n o/w SSSG of -7%) faced very challenging apparel market conditions (declining footfall, deflationary trends, competition from "fast-fashion" brands), especially in the US (-19% FX-n). The group has implemented a few initiatives to restore momentum and streamline the cost structure, which should gradually bear fruits throughout H2 2016 and onwards.
- On the other hand, **Swatch Group** was the worst performer. H1 sales were down 12.5% at same forex. Over the first six months, Swiss watch exports declined 11% including -27% in Hong Kong This clearly negative trend was driven by Switzerland, Hong Kong and France that together account for 30% of group sales and we assume a 20% sales decline for these three areas. Beyond the watch brand sales decline, the movements production business was penalised by order cancellations. Only Harry Winston revenues were up in H1. The Swatch Group profitability declined severely in H1 at -870bp to 9.5% as Nick Hayek, Group CEO, did not want to adjust costs and particularly by cutting jobs, hence a very strong deleverage impact. It is worth noting that between 2013 and 2016, the group's margin lost almost 1,300bp from 24.5% to 11.5%!!

VALUATION

- Over the last 3m, among our luxury sample, the best performer was Hermès with a 25% hike vs a 6% increase on average. But Kering and LVMH also performed quite well. Nevertheless, YTD, luxury stock share prices have fallen 2% on average (+3% vs DJ Stoxx), with again Moncler, Hermès, Kering and LVMH as the best performers.
- Despite these performances, we continue to favour these four stocks with around 12% upside for Moncler and LVMH.

3m Stocks performances (in %):




Source: Datastream

NEXT CATALYSTS

• Hermès and Tod's will report their H1 results mid-September.

Click here to download document



BRYAN, GARNIER & CO

Bryan Garnier stock rating system

For the purposes of this Report, the Bryan Garnier stock rating system is defined as follows:

Stock rating

BUY	Positive opinion for a stock where we expect a favourable performance in absolute terms over a period of 6 months from the publication of a
DUT	recommendation. This opinion is based not only on the FV (the potential upside based on valuation), but also takes into account a number of
	elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock
	will feature an introduction outlining the key reasons behind the opinion.

- NEUTRAL Opinion recommending not to trade in a stock short-term, neither as a BUYER or a SELLER, due to a specific set of factors. This view is intended to be temporary. It may reflect different situations, but in particular those where a fair value shows no significant potential or where an upcoming binary event constitutes a high-risk that is difficult to quantify. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.
- SELL Negative opinion for a stock where we expect an unfavourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential downside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.

Distribution of stock ratings

BUY ratings 55,3%

NEUTRAL ratings 33,3%

SELL ratings 11,3%

Research Disclosure Legend

1	Bryan Garnier shareholding in Issuer	Bryan Garnier & Co Limited or another company in its group (together, the "Bryan Garnier Group") has a shareholding that, individually or combined, exceeds 5% of the paid up and issued share capital of a company that is the subject of this Report (the "Issuer").	No
2	Issuer shareholding in Bryan Garnier	The Issuer has a shareholding that exceeds 5% of the paid up and issued share capital of one or more members of the Bryan Garnier Group.	No
3	Financial interest	A member of the Bryan Garnier Group holds one or more financial interests in relation to the Issuer which are significant in relation to this report	No
4	Market maker or liquidity provider	A member of the Bryan Garnier Group is a market maker or liquidity provider in the securities of the Issuer or in any related derivatives.	No
5	Lead/co-lead manager	In the past twelve months, a member of the Bryan Garnier Group has been lead manager or co-lead manager of one or more publicly disclosed offers of securities of the Issuer or in any related derivatives.	No
6	Investment banking agreement	A member of the Bryan Garnier Group is or has in the past twelve months been party to an agreement with the Issuer relating to the provision of investment banking services, or has in that period received payment or been promised payment in respect of such services.	No
7	Research agreement	A member of the Bryan Garnier Group is party to an agreement with the Issuer relating to the production of this Report.	No
8	Analyst receipt or purchase of shares in Issuer	The investment analyst or another person involved in the preparation of this Report has received or purchased shares of the Issuer prior to a public offering of those shares.	No
9	Remuneration of analyst	The remuneration of the investment analyst or other persons involved in the preparation of this Report is tied to investment banking transactions performed by the Bryan Garnier Group.	No
10	Corporate finance client	In the past twelve months a member of the Bryan Garnier Group has been remunerated for providing corporate finance services to the issuer or may expect to receive or intend to seek remuneration for corporate finance services from the Issuer in the next six months.	No
11	Analyst has short position	The investment analyst or another person involved in the preparation of this Report has a short position in the securities or derivatives of the Issuer.	No
12	Analyst has long position	The investment analyst or another person involved in the preparation of this Report has a long position in the securities or derivatives of the Issuer.	No
13	Bryan Garnier executive is an officer	A partner, director, officer, employee or agent of the Bryan Garnier Group, or a member of such person's household, is a partner, director, officer or an employee of, or adviser to, the Issuer or one of its parents or subsidiaries. The name of such person or persons is disclosed above.	No
14	Analyst disclosure	The analyst hereby certifies that neither the views expressed in the research, nor the timing of the publication of the research has been influenced by any knowledge of clients positions and that the views expressed in the report accurately reflect his/her personal views about the investment and issuer to which the report relates and that no part of his/her remuneration was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in the report.	Yes
15	Other disclosures	Other specific disclosures: Report sent to Issuer to verify factual accuracy (with the recommendation/rating, price target/spread and summary of conclusions removed).	No

A copy of the Bryan Garnier & Co Limited conflicts policy in relation to the production of research is available at www.bryangarnier.com

BRYAN, GARNIER & CO

London	Paris	New York	Munich	New Delhi	
Beaufort House	26 Avenue des Champs Elysées	750 Lexington Avenue	Widenmayerstrasse 29	The Imperial Hotel Janpath	
15 St. Botolph Street	75008 Paris	New York, NY 10022	80538 Munich	New Delhi 110 001 Tel +91 11 4132 6062	
London EC3A 7BB	Tel: +33 (0) 1 56 68 75 00	Tel: +1 (0) 212 337 7000	Germany	+91 98 1111 5119	
Tel: +44 (0) 207 332 2500	Fax: +33 (0) 1 56 68 75 01	Fax: +1 (0) 212 337 7002	+49 89 2422 62 11	Fax +91 11 2621 9062	
Fax: +44 (0) 207 332 2559	Regulated by the	FINRA and SIPC member		Geneva	
Authorised and regulated by the	Financial Conduct Authority (FCA) and the			rue de Grenus 7 CP 2113	
Financial Conduct Authority (FCA)	Autorité de Contrôle prudential et de			Genève 1, CH 1211	
	resolution (ACPR)			Tel +4122 731 3263	

Important information

This document is classified under the FCA Handbook as being investment research (independent research). Bryan Garnier & Co Limited has in place the measures and arrangements required for investment research as set out in the FCA's Conduct of Business Sourcebook.

Fax+4122731 3243 Regulated by the FINMA

This report is prepared by Bryan Garnier & Co Limited, registered in England Number 03034095 and its MIFID branch registered in France Number 452 605 512. Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 178733) and is a member of the London Stock Exchange. Registered address: Beaufort House 15 St. Botolph Street, London EC3A 7BB, United Kingdom

This Report is provided for information purposes only and does not constitute an offer, or a solicitation of an offer, to buy or sell relevant securities, including securities mentioned in this Report and options, warrants or rights to or interests in any such securities. This Report is for general circulation to clients of the Firm and as such is not, and should not be construed as, investment advice or a personal recommendation. No account is taken of the investment objectives, financial situation or particular needs of any person.

The information and opinions contained in this Report have been compiled from and are based upon generally available information which the Firm believes to be reliable but the accuracy of which cannot be guaranteed. All components and estimates given are statements of the Firm, or an associated company's, opinion only and no express representation or warranty is given or should be implied from such statements. All opinions expressed in this Report are subject to change without notice. To the fullest extent permitted by law neither the Firm nor any associated company accept any liability whatsoever for any direct or consequential loss arising from the use of this Report. Information may be available to the Firm or an associated companies which are not reflected in this Report. The Firm or an associated company may have a consulting relationship with a company which is the subject of this Report.

This Report may not be reproduced, distributed or published by you for any purpose except with the Firm's prior written permission. The Firm reserves all rights in relation to this Report.

Past performance information contained in this Report is not an indication of future performance. The information in this report has not been audited or verified by an independent party and should not be seen as an indication of returns which might be received by investors. Similarly, where projections, forecasts, targeted or illustrative returns or related statements or expressions of opinion are given ("Forward Looking Information") they should not be regarded as a guarantee, prediction or definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. A number of factors, in addition to the risk factors stated in this Report, could cause actual results to differ materially from those in any Forward Looking Information.

Disclosures specific to clients in the United Kingdom

This Report has not been approved by Bryan Garnier & Co Limited for the purposes of section 21 of the Financial Services and Markets Act 2000 because it is being distributed in the United Kingdom only to persons who have been classified by Bryan Garnier & Co Limited as professional clients or eligible counterparties. Any recipient who is not such a person should return the Report to Bryan Garnier & Co Limited and should not rely on it for any purposes whatsoever.

This research report (the "Report") was prepared by Bryan Garnier & Co Limited for information purposes only. The Report is intended for distribution in the United States to "Major US Institutional Investors" as defined in SEC Rule 15a-6 and may not be furnished to any other person in the United States. Each Major US Institutional Investor which receives a copy of this Report by its acceptance hereof represents and agrees that it shall not distribute or provide this Report to any other person. Any US person that desires to effect transactions in any security discussed in this Report should call or write to our US affiliated broker, Bryan Garnier Securities, LLC. 750 Lexington Avenue, New York NY 10022. Telephone: 1-212-337-7000.

This Report is based on information obtained from sources that Bryan Garnier & Co Limited believes to be reliable and, to the best of its knowledge, contains no misleading, untrue or false statements but which it has not independently verified. Neither Bryan Garnier & Co Limited and/or Bryan Garnier Securities LLC make no guarantee, representation or warranty as to its accuracy or completeness. Expressions of opinion herein are subject to change without notice. This Report is not an offer to buy or sell any security.

Bryan Garnier Securities, LLC and/or its affiliate, Bryan Garnier & Co Limited may own more than 1% of the securities of the company(ies) which is (are) the subject matter of this Report, may act as a market maker in the securities of the company(ies) discussed herein, may manage or co-manage a public offering of securities for the subject company(ies), may sell such securities to or buy them from customers on a principal basis and may also perform or seek to perform investment banking services for the company(ies).

Bryan Garnier Securities, LLC and/or Bryan Garnier & Co Limited are unaware of any actual, material conflict of interest of the research analyst who prepared this Report and are also not

aware that the research analyst knew or had reason to know of any actual, material conflict of interest at the time this Report is distributed or made available..

BRYAN, GARNIER & CO